AbouEzzeddine Omar F, French Benjamin, Mirzoyev Sultan A, Jaffe Allan S, Levy Wayne C, Fang James C, Sweitzer Nancy K, Cappola Thomas P, Redfield Margaret M
Department of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, Minnesota, USA; Mayo Graduate School, Mayo Clinic and Foundation, Rochester, Minnesota, USA.
Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
J Heart Lung Transplant. 2016 Jun;35(6):714-21. doi: 10.1016/j.healun.2016.01.016. Epub 2016 Jan 15.
Heart failure (HF) guidelines recommend brain natriuretic peptide (BNP) and multivariable risk scores, such as the Seattle Heart Failure Model (SHFM), to predict risk in HF with reduced ejection fraction (HFrEF). A practical way to integrate information from these 2 prognostic tools is lacking. We sought to establish a SHFM+BNP risk-stratification algorithm.
The retrospective derivation cohort included consecutive patients with HFrEF at the Mayo Clinic. One-year outcome (death, transplantation or ventricular assist device) was assessed. The SHFM+BNP algorithm was derived by stratifying patients within SHFM-predicted risk categories (≤2.5%, 2.6% to ≤10%, >10%) according to BNP above or below 700 pg/ml and comparing SHFM-predicted and observed event rates within each SHFM+BNP category. The algorithm was validated in a prospective, multicenter HFrEF registry (Penn HF Study).
Derivation (n = 441; 1-year event rate 17%) and validation (n = 1,513; 1-year event rate 12%) cohorts differed with the former being older and more likely ischemic with worse symptoms, lower EF, worse renal function and higher BNP and SHFM scores. In both cohorts, across the 3 SHFM-predicted risk strata, a BNP >700 pg/ml consistently identified patients with approximately 3-fold the risk that the SHFM would have otherwise estimated, regardless of stage of HF, intensity and duration of HF therapy and comorbidities. Conversely, the SHFM was appropriately calibrated in patients with a BNP <700 pg/ml.
The simple SHFM+BNP algorithm displays stable performance across diverse HFrEF cohorts and may enhance risk stratification to enable appropriate decision-making regarding HF therapeutic or palliative strategies.
心力衰竭(HF)指南推荐使用脑钠肽(BNP)和多变量风险评分,如西雅图心力衰竭模型(SHFM),来预测射血分数降低的心力衰竭(HFrEF)患者的风险。目前缺乏一种将这两种预后工具的信息整合起来的实用方法。我们试图建立一种SHFM+BNP风险分层算法。
回顾性推导队列包括梅奥诊所连续的HFrEF患者。评估一年的结局(死亡、移植或心室辅助装置)。SHFM+BNP算法是通过根据BNP高于或低于700 pg/ml,将患者在SHFM预测的风险类别(≤2.5%、2.6%至≤10%、>10%)内进行分层,并比较每个SHFM+BNP类别中SHFM预测的和观察到的事件发生率而得出的。该算法在前瞻性多中心HFrEF注册研究(宾夕法尼亚心力衰竭研究)中得到验证。
推导队列(n = 441;一年事件发生率17%)和验证队列(n = 1513;一年事件发生率12%)有所不同,前者年龄更大,更可能为缺血性,症状更严重,射血分数更低,肾功能更差,BNP和SHFM评分更高。在两个队列中,在3个SHFM预测的风险分层中,无论HF的阶段、HF治疗的强度和持续时间以及合并症如何,BNP>700 pg/ml始终能识别出风险约为SHFM原本估计值3倍的患者。相反,在BNP<700 pg/ml的患者中,SHFM得到了适当的校准。
简单的SHFM+BNP算法在不同的HFrEF队列中表现出稳定的性能,可能会加强风险分层,以便就HF治疗或姑息治疗策略做出适当的决策。